BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease
CAMBRIDGE, Mass., July 19, 2021 -- (Healthcare Sales & Marketing Network) -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has grant... Regenerative Medicine, Neurology, FDA BlueRock Therapeutics, Bayer, Parkinson's disease, engineered cell therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Food and Drug Administration (FDA) | Grants | Marketing | Neurology | Parkinson's Disease | Pharmaceuticals